

ASX Announcement

Date: September 10, 2010

Shareholder Update

ARTES Biotechnology GmbH to acquire Select Vaccines' ANAVAX™ VLP technology.

Select Vaccines Ltd is pleased to announce that it has entered into an agreement with the German company ARTES Biotechnology GmbH under which ARTES will acquire Select's ANAVAX™ virus-like-particle technology. ARTES will offer the technology to clients primarily in conjunction with its proprietary yeast-based expression systems. Select will receive an upfront payment together with double-digit royalties on sales revenues obtained by ARTES.

ARTES (www.artes-biotechnology.com) is a profitable, privately-held company based in Langenfeld, Germany focused on production cell line and process development for pharmaceutical and chemical industry. ARTES holds exclusive rights to the patented yeast *Hansenula polymorpha* protein expression system, which is approved worldwide for production of a.o. HepB vaccines..

The ANAVAX™ technology was developed by scientists at the Burnet Institute in Melbourne. The Burnet Institute will receive a royalty-free, non-exclusive licence from ARTES to use the ANAVAX™ technology to develop vaccines against malaria and HIV.

Burnet Institute to acquire the right to develop Select Vaccines' diagnostic and antiviral therapy technologies.

Select Vaccines is pleased to announce that it has signed a binding Heads of Agreement with the Burnet Institute for the Burnet Institute to acquire the rights to commercialise the Select's portfolio of diagnostic and antiviral therapy technologies. These technologies were invented by the Burnet Institute scientists and have been developed by Select in collaboration with the Burnet Institute and the Howard Florey Institute in Melbourne. Select will receive a share of the future proceeds of commercialisation earned by the Burnet Institute from the development of these technologies.

Completion of placement of shares in Select Vaccines Ltd

Select Vaccines Ltd (ASX: SLT) ("**Select**") is pleased to announce that it has completed the placement of 38.3 million fully paid ordinary shares to professional and sophisticated investors at the price of \$0.003 per share to raise \$114,907 to augment working capital, as foreshadowed in the Select's announcement on September 6, 2010.

Contact details

Select Vaccines Ltd:

- Dr Ian Cooke, Director, tel 0409 791 550, email ian.cooke@foursight.com.au

ARTES Biotechnology GmbH

- Dr. Melanie Dröttboom, Business Development Director, tel +49 2173 27587 12, email m.droettboom@artes-biotechnology.com,

Burnet Institute

- A/Prof David Anderson, Head, Business Development Office tel (03) 9282 2239, email Anderson@burnet.edu.au